Hyderabad: A research team from Hyderabad has found that Ertugliflozin anti-diabetes drugs can work against Covid-19.
Researchers from the Reagene Innovations Private Limited, a startup company incubated at the Aspire-Blionest, sponsored by the University of Hyderabad and the Department of Biotechnology (DBT), and Indra Private Limited has reasons for Ertugliflozin’s anti-diabetes drugs as drugs returned from studies in -Vitro and in-silico, may be able to provide a therapeutic solution for Covid-19 infection for Ace2 humans (receptors that bind the Covid-19 virus itself) but also display significant anti-inflammatory and antithrombotic nature in 3D human vascular lung models , both of which are fundamentally in Covid-19 infection.
This is the first result that offers a safe, ready-saving solution for humans who contract Covid-19.
“It has great potential to treat Covid-19 infections, and our research proves its efficacy in the test-tube test”, said Dr.
Uday Saxena, CEO of Reagene Innovation, was established together with Dr.
Subramanyam Vangala, and Dr Sreedhara Voleti, MD from Indra.
Ertugliflozin is a drug approved by the FDA for type-2 diabetes, working as an SGLT-2 inhibitor by removing excessive glucose through urine.
Happy! You have managed to throw your voteogin to see the results
Indra’s focus is in the consultation, contract, and collaborative solution for silico drug design, has prioritized around 8000 drugs that FDA approved to top-10 of their computing studies, which further experimented with innovation reagene for various cytokine tests on cytokine storms, properties Antitrombotic, and reduction of inflammatory markers through various in vitro tests, according to an official statement from the University of Hyderabad.
The road to find critically critically planned drugs is planned and completed in one year of funds from the IT giant, Tech Mahindra.
Tech Mahindra Team is efficiently led by Dr.
Ratnakar Palakodeti, Head of Global Practice Science, and Nikhil Malhotra, Head of Global Makers Lab along with Indra’s scientific partnerships and reagene, bringing this useful innovation is very helpful for humanity -19.
The results of the results of this study were recently published in journals (Biorxiv) and patents proposed both in India and PCT.
“We have found a molecule that has the potential to attack Coronavirus.
We have submitted a common patent,” Malhotra said.
The results obtained are very encouraging, and further in the animal model on preclinical results, and clinically in humans have not been carried out for this drug officially nominated as a therapeutic agent for Covid.
-19.
The Aspire-Bionest is an incubator of the life science funded by BIRAC, a non-profit organization from the Department of Biotechnology, the Government.
From India, and the University of Hyderabad (UOH) to maintain arbiter technology through entrepreneurship located in the Hyderabad University Life Sciences School with a commitment to maintain start-ups such as Reagene Innovation, helping them achieve the purpose of the play facility.